Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of Wednesday, September 9, 2026.
FORWARD PE RATIO
N/A
BioNTech SE
Market Cap
$24.67B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| BioNTech SE (BNTX) | $24.67B | N/A |
| West Pharmaceutical Services, Inc. (WST)vs › | $23.84B | 37.67 |
| Incyte Corporation (INCY)vs › | $25.71B | 33.06 |
| Quest Diagnostics Incorporated (DGX)vs › | $25.90B | 21.04 |
| Mettler-Toledo International Inc. (MTD)vs › | $26.18B | 28.01 |
| Labcorp Holdings Inc. (LH)vs › | $26.36B | 17.70 |
| United Therapeutics Corporation (UTHR)vs › | $21.45B | 19.05 |
| STERIS plc (STE)vs › | $21.03B | 21.42 |
| Medline Inc. (MDLN)vs › | $28.80B | 23.24 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $29.54B | 13.56 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
Consensus estimates for this stock are reported in EUR, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
